Fig. 5. Compound-110 reverses MK-801-induced hyperlocomotion without inducing catalepsy.

a Brain penetration of compound-110 in mice (n = 3) after 1 mg/kg compound-110 intraperitoneally (i.p.) administration. b i.p. administration of compound-110 dose-dependently reverses MK-801-induced hyperlocomotion. c The median effective dose (ED₅₀) of compound-110 is calculated from total traveled distance in 0–45 min interval in a after MK-801 administration using ‘one-phase-exponential decay’ method. d Compound-110 does not elicit recognizable catalepsy; haloperidol (1 mg/kg) is used as the positive control to elicit catalepsy as assessed by latency to movement, p-value is calculated using unpaired t-test. Data are shown as mean ± SEM of 8 animals per group in b–d. Source data are provided as a Source Data file.